Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
No Summary
ACS Med Chem Lett
ISSN 1948-5875
11 papers in the library · 6 citations · publishing 2023-2026
Papers
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
ACS Med Chem Lett August 18, 2023 Robert B. Kargbo 3 citations
This viewpoint argues that combining biomarkers, psychedelics, and artificial intelligence could improve psychiatric diagnostics, prognosis, and treatment. Psychedelics show promise in therapy, and AI may help predict how individuals will respond to treatments. However, significant challenges remain, including ethical and practical hurdles. The authors call for further research to develop more precise, personalized psychiatric care.
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
No Summary
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
The text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett January 4, 2025 Ram W. Sabnis
The text describes a class of novel chemical compounds, 3-cycloaminoindoles, that act as serotonergic psychedelic agents. These compounds are proposed for potential therapeutic use in treating psychosis, mental illness, and other central nervous system (CNS) disorders. The abstract indicates the compounds are designed to interact with serotonin receptors, a common target for psychedelic and psychiatric drugs, but provides no experimental data, results, or evidence of efficacy.
Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.
ACS Med Chem Lett November 11, 2024 Robert B. Kargbo
Three new classes of psilocin-related compounds—4-pivaloyloxy-N-methyltryptammonium chloride, alkyl quaternary ammonium tryptamines, and 4-pivaloyloxy-N-methyltryptammonium derivatives—have been developed to improve stability, bioavailability, and efficacy for treating depression, anxiety, and substance use disorders. Preclinical studies indicate these innovations may overcome limitations of traditional psychedelics, offering more reliable therapeutic options for mental and neurological disorders.
From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic Therapeutics.
ACS Med Chem Lett January 12, 2026
Psychedelic drug development is moving beyond isolated molecules and subjective experiences toward integrated therapeutic systems. Two recent patent applications illustrate this shift: one optimizes the solid-state form of a lysergamide analogue for reliable manufacturing and stability, and the other uses machine-learning-based neurophysiological biomarkers to predict how individual patients will respond. Together, these approaches target complementary challenges in translating psychedelic treatments from research to clinical practice.
Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.
ACS Med Chem Lett January 12, 2026
Recent patent applications show a strategic shift in psychedelic development from experiential treatments toward chemically and pharmacokinetically precise neurotherapeutics. Four patent applications collectively cover solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor pharmacology. These disclosures outline a platform-level evolution toward reproducible, mechanism-informed psychedelic medicines.
Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.
ACS Med Chem Lett November 10, 2025
Recent patents describe a new generation of psychedelic analogs designed to modulate the 5-HT2A receptor more precisely, with fewer side effects and adjustable duration. By modifying the chemical structures of DMT and psilocin—using prodrug strategies, adding fluorine atoms, and exploring structure-activity relationships—these innovations aim to create safer, shorter-acting psychedelic medications that fit better into clinical settings and offer more predictable therapeutic effects for psychiatric conditions.
Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
ACS Med Chem Lett October 9, 2025
Recent patents describe complementary strategies to improve psychedelic-assisted therapy. Novel psilocin prodrugs offer better pharmacokinetics and stability, while digital systems allow monitoring of cognitive states during treatment. Parallel developments combine neuroplastogen drugs with transcranial electrical stimulation, using a model-driven approach to enhance and personalize neural plasticity. These innovations together suggest a precision framework for treating neuropsychiatric disorders.
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett February 11, 2025
The text describes novel compounds that act as 5-HT2A agonists, which are being developed for treating mental illness or central nervous system disorders. These compounds target the serotonin 2A receptor, a common site for psychedelic and psychiatric drugs. The work likely involves the design, synthesis, or characterization of these compounds as potential therapeutics, though no specific findings, data, or results are provided in this abstract.